CNS Pharmaceuticals, Inc.
CNSP
$6.12
-$0.42-6.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.16% | -21.34% | 40.91% | -23.95% | 37.06% |
| Total Depreciation and Amortization | 37.50% | 37.50% | 0.00% | -11.11% | -20.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -90.70% | -69.22% | -44.10% | 344.04% | -19.12% |
| Change in Net Operating Assets | -563.54% | 567.94% | -193.09% | -317.12% | 96.86% |
| Cash from Operations | -223.76% | -1.56% | -115.70% | -101.40% | 51.50% |
| Capital Expenditure | -- | -- | -90.91% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -90.91% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 1.11% | 0.91% | 55.87% | 26.02% | 26.73% |
| Issuance of Common Stock | 85.53% | 154.72% | 104.17% | 9,240.56% | -9.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | 95.07% | -- | -- |
| Cash from Financing | 90.21% | 184.16% | 127.91% | 146,109.52% | -9.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -235.69% | 2,371.37% | -41.82% | 262.67% | 181.35% |